Clinical classification in mental health at the cross-roads: Which direction next?

IB Hickie; J Scott; DF Hermens; EM Scott; SL Naismith; AJ Guastella; N Glozier; PD McGorry

Journal article

Clinical classification in mental health at the cross-roads: Which direction next?

IB Hickie, J Scott, DF Hermens, EM Scott, SL Naismith, AJ Guastella, N Glozier, PD McGorry

BMC Medicine | BMC | Published : 2013

DOI: 10.1186/1741-7015-11-125

Download PDF

Abstract

Background: After 30 years of consensus-derived diagnostic categories in mental health, it is time to head in new directions. Those categories placed great emphasis on enhanced reliability and the capacity to identify them via standardized checklists. Although this enhanced epidemiology and health services planning, it failed to link broad diagnostic groupings to underlying pathophysiology or specific treatment response.Discussion: It is time to adopt new goals that prioritize the validation of clinical entities and foster alternative strategies to support those goals. The value of new dimensions (notably clinical staging), that are both clinically relevant and directly related to emerging d..

View full abstract

University of Melbourne Researchers

Patrick McGorry Author

Related Projects (2)

EMERGING MENTAL DISORDERS IN YOUNG PEOPLE: USING CLINICAL STAGING FOR PREDICTION, PREVENTION AND EARLY INTERVENTION

Mental disorders are a major cause of disability in Australia, especially for young people. We have developed a clinical staging model cover..

EMERGING MENTAL DISORDERS IN YOUNG PEOPLE: USING CLINICAL STAGING FOR PREDICTION, PREVENTION AND EARLY INTERVENTION

Mental disorders are a major cause of disability in Australia, especially for young people. We have developed a clinical staging model cover..

Grants

Awarded by Pfizer

Funding Acknowledgements

IBH was a director of headspace: the national youth mental health foundation until January 2012. He is the executive director of the Brain and Mind Research Institute (BMRI), which operates two early-intervention youth services under contract to headspace. He is a member of the new Australian National Mental Health commission and was previously the CEO of beyondblue: the national depression initiative. He has led a range of community-based and pharmaceutical industry-supported depression awareness and education and training programs. He has led depression and other mental health research projects that have been supported by a variety of pharmaceutical partners. Current investigator-initiated studies are supported by Servier and Pfizer. He has received honoraria for his contributions to professional educational seminars related to depression, youth mental health and circadian-rhythms research. DFH has received honoraria for educational seminars from Janssen-Cilag. EMS is the (unpaid) Clinical Director of Headspace Services at the BMRI, the (unpaid) Coordinator of the Youth Mental Health Research Program at the BMRI, and Deputy Director of St Vincent's Private Hospital Young Adult Mental Health Unit. She has received honoraria for educational seminars related to the clinical management of depressive disorders supported by Servier and Eli Lilly pharmaceuticals. She has participated in a national advisory board for the antidepressant compound Pristiq, manufactured by Pfizer. PDM is director of headspace and also of Headstrong (Irish National YMH Foundation) and he holds Investigator Initiated Research Grant Support from Janssen Cilag, Eli Lilly, BMS and Astra Zeneca. PDM also has consultancy and advisory roles with Janssen Cilag, Eli Lilly, BMS, AZ Roche and Pfizer.IBH, DFH and AJG are supported by an NHMRC Australia Fellowship awarded to IBH (464914). SLN is funded by an NHMRC Clinical Research Fellowship (402864). This work was further supported by NHMRC Program Grant (566529).